<DOC>
	<DOC>NCT01421069</DOC>
	<brief_summary>This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3 subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis related arthritis (ERA), or psoriatic arthritis (PsA)] who have completed approximately 96 weeks of participation in study 0881A1-3338 (B1801014). The study contains an active treatment period, withdrawal/re-treatment period and a observational period (non-treatment).</brief_summary>
	<brief_title>Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Receipt of at least 1 dose of investigational product (etanercept) and participation for approximately 96 weeks in study 0881A13338 (B1801014) Personally signed and dated informed consent document (and assent document, as applicable) indicating the subject (or legally representative/guardian) has been informed of all pertinent aspects of the study. Exclusion criteria for subject planning to continue investigational product: withdrawal from investigational product in study 0881A13338 for any reason (safety or nonsafety). History of maliginancy other than squamous cell, basal cell carcinoma or cervical carcinoma in situ.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Use of etanercept to treat pediatric subjects with extended oligoarticular JIA</keyword>
	<keyword>enthestitis related arthritis (ERA)</keyword>
	<keyword>or psoriatic arthritis (PsA).</keyword>
</DOC>